Source-grounded facts extracted from Oscar Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Oscar Health, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026 at the 2026-06-04 meeting.
“Proposal 3 – Ratification of appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026: Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 819,470,681 710,425 126,391 –”
Oscar Health, Inc. shareholders approved Advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.
“Proposal 2 – Advisory vote to approve named executive officer compensation: Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 765,188,330 8,859,050 329,648 45,930,469”
Oscar Health, Inc. shareholders approved Election of eight director nominees to serve until the 2027 Annual Meeting at the 2026-06-04 meeting.
“Proposal 1 – Election of eight director nominees to serve until the 2027 Annual Meeting: Nominee Votes FOR Votes WITHHELD Broker Non-Votes Mark T. Bertolini 772,818,926 1,558,102 45,930,469 William J. Gassen III 750,059,354 24,317,674 45,930,469 Joshua Kushner 773,650,856 726,172 45,930,469 Laura Lang 773,617,446 759,582 45,930,469 David Alexander Plouffe 770,608,329 3,768,699 45,930,469 Siddhartha Sankaran 771,818,551 2,558,477 45,930,469 Mario Schlosser 773,697,551 679,477 45,930,469 Vanessa Ames Wittman 772,915,630 1,461,398 45,930,469”
Mario Schlosser changed role as Co-Founder & Advisor to the CEO at Oscar Health, Inc..
“Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.”
Oscar Health, Inc. reported first quarter ended March 31, 2026 results: revenue $4,647,194, net income $678,996, EPS $2.07. Guidance reaffirmed.
“results press release dated February 10, 2026. First Quarter 2026 Financial Highlights Three Months Ended March 31, (in thousands, except percentages) 2026 2025 Total revenue $4,647,194 $3,046,263 Medical loss ratio (“MLR”) 70.5% 75.4% Selling, general, and administrative (“SG&A”) expense ratio 15.2% 15.8% Earnings from operations $704,085 $297,123 Net income”
Oscar Health, Inc. incurred revolving credit of $475.0 million with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto at Term SOFR plus a margin of 4.50% per annum, or the Alternate Base Rate plus a ma maturing February 6, 2029.
“On February 6, 2026, Oscar Health, Inc. (the “Company”), entered into a $475.0 million secured three-year revolving credit facility (the “Revolving Credit Facility”), pursuant to a Credit Agreement (the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto.”
Oscar Health, Inc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto valued at $475.0 million (effective 2026-02-06).
“On February 6, 2026, Oscar Health, Inc. (the “Company”), entered into a $475.0 million secured three-year revolving credit facility (the “Revolving Credit Facility”), pursuant to a Credit Agreement (the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto.”
Oscar Health, Inc. issued a maximum of 21,889,982 shares of the Company's class A common stock may be issued upon conversion of the Notes of convertible note to initial purchasers for $410,000,000 aggregate principal amount of 2.25% Convertible Senior Subordinated Notes due 2030, net proceeds approximately $395.8 million.
“accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry Into a Material Definitive Agreement. Indenture and Notes On September 18, 2025, Oscar Health, Inc. (the “ Company ”) issued $410,000,000 aggregate principal amount of its 2.25% Convertible Senior Subordinated Notes due 2030 (the “ Notes ”). The Notes were”
Alessandrea Quane departed as EVP, Chief Insurance Officer at Oscar Health, Inc..
“Alessandrea Quane, the Company’s EVP, Chief Insurance Officer, will cease serving in this role effective as of February 24, 2025 and her employment with the Company and Oscar Management Corporation (“OMC”) will terminate effective as of March 3, 2025.”
Steven Wolin resigned as EVP and Chief Operating Officer at Oscar Health, Inc..
“Steven Wolin resigned as EVP and Chief Operating Officer of the Company, effective as of February 5, 2025.”
Janet Liang was appointed as EVP and President of Oscar Insurance at Oscar Health, Inc..
“appointed Janet Liang as EVP and President of Oscar Insurance, effective February 24, 2025.”
Oscar Health, Inc. reported First Quarter 2024 results: revenue $2.1 billion, net income $177.4 million, EPS $0.62. Guidance reaffirmed.
“Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Results for First Quarter 2024 May 7, 2024 • For the quarter ended March 31, 2024: ◦ Total Revenue of $2.1 billion, a 46% increase YoY ◦ Medical Loss Ratio of 74.2%, a 210 bps improvement YoY ◦ SG&A Expense Ratio of 18.4%, an 870 bps improvement YoY ◦ Net Income attributable to Oscar of $177.4 million, or $0.62 of diluted earnings per share, a $217.1 million improvement YoY”
Oscar Health, Inc. reported Fiscal Year Ending December 31, 2024 results: revenue $8,300,000 to $8,400,000. Guidance initiated.
“The Company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million.”
Oscar Health, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).
“The Company will reaffirm the updated full year 2023 guidance that it provided in its financial results press release for the third quarter of 2023 dated November 7, 2023. The Company will also reaffirm its target of Total Company Adjusted EBITDA profitability in 2024”
Oscar Health, Inc. amended revolving credit of $115,000,000 total commitments with Wells Fargo Bank, National Association at adjusted term SOFR or alternative base rate plus applicable margin of 4.50% for maturing December 28, 2025.
“On December 28, 2023, Oscar Health, Inc. (the “Company”) entered into the Third Amendment to Credit Agreement (the “Third Amendment”) with Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”), Oscar Management Corporation, as a subsidiary guarantor and the lenders party thereto, which amends the Credit Agreement, dated as of February 21, 2021 (as amended by the First Amendment to Credit Agreement, dated as of January 27, 2022, and as further amended by the Second Amendment to Credit Agreement, dated as of July 21, 2023, the “Credit Agreement” and as amended by the Third Amendment, the “Amended Credit Agreement”). The Third Amendment amended the Credit Agreement to, among other things: (i) extend the maturity date of the revolving loan facility (as amended by the Third Amendment, the “Revolving Loan Facility”) to December 28, 2025 and (ii) decrease the total commitments under the Revolving Loan Facility to $115,000,000.”
Oscar Health, Inc. amended Third Amendment to Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, Oscar Management Corporation, as a subsidiary guarantor, and the lenders party thereto valued at $115,000,000 (effective 2023-12-28).
“On December 28, 2023, Oscar Health, Inc. (the “Company”) entered into the Third Amendment to Credit Agreement (the “Third Amendment”) with Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”), Oscar Management Corporation, as a subsidiary guarantor and the lenders party thereto, which amends the Credit Agreement, dated as of February 21, 2021 (as amended by the First Amendment to Credit Agreement, dated as of January 27, 2022, and as further amended by the Second Amendment to Credit Agreement, dated as of July 21, 2023, the “Credit Agreement” and as amended by the Third Amendment, the “Amended Credit Agreement”).”
Oscar Health, Inc. reported the quarter ended September 30, 2023 results: net income Net loss of $65.7 million. Guidance raised.
“Oscar Health, Inc. (the “Company”) announced the Company’s financial results for the quarter ended September 30, 2023.”
Oscar Health, Inc. updated its full year 2023 guidance (reaffirmed).
“Oscar is reaffirming its full year 2023 outlook across all metrics as provided in its financial results press release dated February 9, 2023, with MLR now projected to be towards the low-end of the 82% - 84% range and Adjusted EBITDA 1 projected to be towards the high-end of the ($175) million - ($75) million range, towards a ($75) million loss.”
Siddhartha Sankaran departed as Chief Financial Officer at Oscar Health, Inc..
“Mr. Siddhartha Sankaran will remain CFO through that date.”
R. Scott Blackley changed role as Chief Financial Officer at Oscar Health, Inc..
“Effective August 14, 2023, R. Scott Blackley will become the Company’s Chief Financial Officer (“CFO”).”
Oscar Health, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2023-06-08 meeting.
“Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 752,930,211 667,799 102,007 31,991,728”
Oscar Health, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.
“Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 784,934,535 691,172 66,038 0”
Oscar Health, Inc. shareholders approved Election of ten directors to hold office until the Annual Meeting of Stockholders to be held in 2024 and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal. at the 2023-06-08 meeting.
“Item 1 - Election of ten directors to hold office until the Annual Meeting of Stockholders to be held in 2024 and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal. Nominee Votes FOR Votes WITHHELD Broker Non-Votes Mark T. Bertolini 753,365,522 334,495 31,991,728 Jeffery H. Boyd 741,028,962 12,671,055 31,991,728 William Gassen III 753,175,629 524,388 31,991,728 Joshua Kushner 724,585,176 29,114,841 31,991,728 Laura Lang 753,516,957 183,060 31,991,728 David Plouffe 740,975,413 12,724,604 31,991,728 Elbert O. Robinson, Jr. 752,939,660 760,357 31,991,728 Siddhartha Sankaran 750,099,500 3,600,517 31,991,728 Mario Schlosser 750,505,016 3,195,001 31,991,728 Vanessa A. Wittman 752,949,739 750,278 31,991,728”
Siddhartha Sankaran changed role as Interim Chief Financial Officer at Oscar Health, Inc..
“On May 26, 2023, Oscar Health, Inc. (the “Company”) and Siddhartha Sankaran agreed that Mr. Sankaran will conclude his role as the Company’s Interim Chief Financial Officer as of August 31, 2023”
Oscar Health, Inc. reported the first quarter ended March 31, 2023 results: revenue Premiums earned of $1.4 billion, net income Net loss of $39.6 million. Guidance reaffirmed.
“YoY Improvements Across all KPIs May 9, 2023 • For the quarter ended March 31, 2023: ◦ Direct and Assumed Policy Premiums of $1.7 billion, a 2% increase YoY ◦ Premiums earned of $1.4 billion, a 50% increase YoY ◦ Medical Loss Ratio of 76.3%, a 108 bps improvement YoY ◦ Net loss of $39.6 million, an improvement of $37.7 million YoY ◦ Adjusted EBITDA of $51.1 million,”
Mario Schlosser changed role as President of Technology at Oscar Health, Inc..
“Co-founder Mario Schlosser will move into the role of President of Technology”
Mark T. Bertolini was appointed as Chief Executive Officer at Oscar Health, Inc..
“Mark T. Bertolini will join the Company as Chief Executive Officer and a member of the Company’s Board of Directors”
Oscar Health, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss of $610 million. Guidance reaffirmed.
“On February 9, 2023, Oscar Health, Inc. (the “Company”) announced the Company’s financial results for the fourth quarter and year ended December 31, 2022.”
Oscar Health, Inc. updated its full year 2022 guidance (reaffirmed).
“the Company will reaffirm the updated full year 2022 guidance that it provided in its financial results press release for the third quarter of 2022 dated November 8, 2022.”
Charles E. Phillips, Jr. resigned as Director at Oscar Health, Inc..
“On December 7, 2022, Charles E. Phillips, Jr. notified the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) of his decision to resign from the Board, effective as of December 31, 2022.”
Bill Gassen was appointed as Director at Oscar Health, Inc..
“On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022”
Laura Lang was appointed as Director at Oscar Health, Inc..
“On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022”
Oscar Health, Inc. updated its Full Year 2022 guidance (reaffirmed).
“Oscar is updating its FY22 outlook to reflect the impact of higher membership.”
Oscar Health, Inc. updated its the third quarter ended September 30, 2022 guidance (reaffirmed).
“On November 8 , 2022, Oscar Health, Inc. (the “Company”), announced the Company’s financial results for the quarter ended September 30, 2022.”
Siddhartha Sankaran was appointed as Interim Chief Financial Officer at Oscar Health, Inc..
“On November 7, 2022, the Board of Directors of the Company (the “Board”) appointed R. Scott Blackley as the Chief Transformation Officer of the Company and Siddhartha Sankaran as Interim Chief Financial Officer of the Company, each effective December 1, 2022 (the “Transition Date”).”
R. Scott Blackley was appointed as Chief Transformation Officer at Oscar Health, Inc..
“On November 7, 2022, the Board of Directors of the Company (the “Board”) appointed R. Scott Blackley as the Chief Transformation Officer of the Company and Siddhartha Sankaran as Interim Chief Financial Officer of the Company, each effective December 1, 2022 (the “Transition Date”).”
Teri List resigned as Director at Oscar Health, Inc..
“On April 5, 2022, Teri List resigned from the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”), effective as of April 8, 2022.”
Meghan Joyce resigned as Chief Operating Officer at Oscar Health, Inc..
“On March 7, 2022, Meghan Joyce notified Oscar Heath, Inc. (the “Company”) that she is resigning effective on April 10, 2022 after a successful tenure as the Chief Operating Officer and Executive Vice President of Platform to be the CEO of a new venture.”
Joel Klein changed role as Senior Advisor to the Chief Executive Officer at Oscar Health, Inc..
“On December 17, 2021, Oscar Health, Inc. (the “Company”) and Joel Klein agreed that Mr. Klein would transition from his role as Chief Policy and Strategy Officer of the Company to a role as a Senior Advisor to the Chief Executive Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.